Are you taking one of these 9 "memory erasing" prescriptions?‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎



<[link removed]>

August 27


 



Urgent: Common prescription drug now linked to Alzheimer's?

See the List →
<[link removed]>

 







Are you taking one of these 9 "memory erasing" prescriptions?
<[link removed]>

You may think your memory loss is just a sign of getting older, but one of
these9 drugs
<[link removed]>
could actually be damaging your brain...

These 9 prescription drugs
<[link removed]>
have now been linked to Alzheimer's disease diagnoses.

If you're over the age of 60, and you're taking even 1 of these 9 drugs, your
brain could be at risk.



Click here to learn more.
<[link removed]>

<[link removed]>
- Kelly

P.S. These "memory erasing" drugs could affect more than 1,429,000 American
seniors this year alone --including you or your spouse. Click here to see the
list of drugs before it's too late...
<[link removed]>
 








CONNOR'S HEALTH NOTES

Burden Is Cumulative and It Is Measurable

Connor Hill · InsightfulWord · August 27, 2026

Nobody should stop a prescribed medication on the basis of a list read online.
Several of the drugs discussed below are prescribed for conditions where abrupt
withdrawal is itself dangerous — seizure disorders, psychiatric illness,
Parkinson's disease — and stopping without a plan can cause harm considerably
faster than the risk being avoided. Everything that follows is material for a
conversation with a prescriber, and the conversation is a reasonable one to
request.

With that stated: there is a real body of evidence here, it is better than
most of what circulates on this subject, and it is worth understanding
precisely because the honest version is more useful than the alarming one.

The drugs concerned are not a list of nine. They are a pharmacological
property shared across many classes. Anticholinergic activity means a drug
blocks acetylcholine, a neurotransmitter involved in memory, attention and a
great deal else. Some medicines are prescribed for that effect. Many others
have it as an unintended side property, and their prescribers may not think of
them in those terms at all.

The largest study of the question examined records for 58,769 patients with a
dementia diagnosis and225,574 matched controls. In the highest exposure
category — more than three years of daily-equivalent use in the period one to
eleven years before diagnosis — the adjusted odds ratio was1.49, with a
confidence interval of 1.44 to 1.54.

The associations were strongest for specific classes: antipsychotics, drugs
for bladder overactivity, antiparkinson drugs, antiepileptics and
antidepressants. Antihistamines and gastrointestinal antispasmodics, which also
carry anticholinergic activity, showed no significant association in the same
analysis.

Two features of that result deserve stating together. The association is
dose-dependent, which strengthens a causal interpretation. And the authors
themselves wrote that they could not entirely exclude the possibility that the
drugs were prescribed for early symptoms of dementia not yet diagnosed — which
would produce the same statistics with the causal arrow reversed.

What follows is what anticholinergic burden means, what the scoring systems
do, why reverse causation is a serious rival explanation, what deprescribing
involves, and what to ask at a medication review.

What Burden Actually Means

The concept that makes this subject tractable is that anticholinergic effect
is additive across a person's whole medication list.

A patient taking one drug with strong anticholinergic activity and three with
mild activity may carry a greater total burden than a patient taking one strong
drug alone. Since the drugs are frequently prescribed by different clinicians
for unrelated conditions, nobody in the chain necessarily sees the total.

Scoring systems exist to quantify it. Several are in use, and the common
design assigns each drug a score — typically zero to three — reflecting the
strength of its anticholinergic activity, and sums the scores across the
current list. A total at or above three is conventionally treated as clinically
significant.


🩺 Clinical Signal

Adjusted odds ratio 1.49

Association between the highest category of cumulative anticholinergic
exposure and later dementia diagnosis, in a study of 58,769 cases and 225,574
matched controls, with a 95 percent confidence interval of 1.44 to 1.54. The
authors reported a population-attributable fraction of about 10 percent and
stated they could not entirely exclude prescribing for early undiagnosed
symptoms. Source: Coupland et al.,JAMA Internal Medicine, anticholinergic drug
exposure and the risk of dementia.


Support or oppose: should anticholinergic burden be calculated automatically
at every prescription?

Supporters argue that the scoring is arithmetic a computer does instantly,
that no single prescriber currently sees the total, and that flagging a high
score at the point of prescribing is the only intervention that reaches the
decision in time. Opponents answer that alert fatigue is a documented and
serious problem, that scales disagree with each other about which drugs count,
and that a flag which fires constantly is ignored constantly. Which risk is
larger?Hit reply — one line is enough.

The scales are imperfect and they disagree. A drug scored two on one scale may
be scored zero on another, because the underlying evidence — laboratory
measures of receptor binding, clinical observation, expert judgment — is
assembled differently in each. That disagreement is a genuine limitation and it
is why a score prompts a review rather than settling one.

What the concept does well is convert a vague concern into a number a
clinician can act on, and identify the patients most likely to benefit from a
look at the whole list.

The population it applies to is larger than most people assume. Surveys of
prescribing in older adults have repeatedly found that a substantial minority
carry a clinically significant burden score, and that the drugs producing it
are ordinary rather than exotic — treatments for bladder symptoms, sleep,
allergy, depression and nausea. This is not a question about unusual medicines;
it is a question about common ones taken together.


The Short-Term Effects Are Not in Dispute

A distinction is worth drawing between two separate questions that get merged.

That anticholinergic drugs cause acute cognitive effects is well established
and not controversial. Confusion, drowsiness, impaired attention, dry mouth,
constipation, urinary retention and blurred vision are recognized effects, and
older adults are more susceptible because of changes in drug clearance and in
the brain's cholinergic reserve.

Those effects are reversible. They appear within days of starting or
increasing a drug and resolve when it is stopped or reduced. Delirium in
hospitalized older patients is frequently precipitated by exactly this
mechanism, and identifying it is routine clinical work.

The contested question is different: whether cumulative exposure over years
increases the risk of a permanent neurodegenerative condition. That is what the
large observational studies address, and it is where the uncertainty sits.

Keeping the two apart matters practically. A person experiencing fogginess
after a recent prescription change has a plausible and immediately actionable
explanation. A person worried about a diagnosis in a decade is asking a
question the evidence answers less confidently.

The acute effects also matter for a reason that has nothing to do with
dementia. Impaired attention and drowsiness raise the risk of falls, and a fall
producing a hip fracture in an older adult carries a mortality and disability
burden that dwarfs most of what is discussed in this area. Fall risk is the
outcome most reliably improved by reducing burden, and it is the one least
often mentioned in material about these drugs.


Why Reverse Causation Is a Serious Rival

The alternative explanation for the association is specific and cannot be
dismissed as a technicality.

Dementia has a prodromal phase lasting years, during which symptoms appear
that are not recognized as dementia. Depression, anxiety, sleep disturbance and
urinary problems are all documented features of that phase.


Context — the medication changes that need supervision

Several classes discussed here cannot be stopped abruptly without risk.
Antiepileptic drugs stopped suddenly can precipitate seizures, including in
people taking them for other indications. Antipsychotics and antidepressants
have withdrawal syndromes and risks of relapse. Antiparkinson medication
withdrawal can cause a severe and occasionally life-threatening syndrome. The
safe route in every case is a planned reduction supervised by the prescriber,
frequently over weeks. Separately, new confusion developing over hours or days
is not a medication review question — it is a reason for urgent assessment,
because delirium has causes including infection that require treatment.

Each of those is treated with drugs carrying anticholinergic activity. A
person in the early undiagnosed phase of dementia may therefore accumulate
exposure because of the disease rather than developing the disease because of
the exposure.

The study designs address this partially. Restricting exposure windows to
periods long before diagnosis — the analysis above used one to eleven years
prior — reduces the problem without eliminating it, since the prodrome can be
long. Excluding the years immediately before diagnosis does the same.

Nobody has run the trial that would settle it, and nobody is going to:
randomizing people to years of anticholinergic exposure is not ethically
available. What exists instead is a consistent, dose-dependent association
across multiple independent datasets, alongside a plausible confounder that
cannot be fully excluded. That is a genuinely unresolved state and it should be
described as one.


What Deprescribing Involves

The clinical response to this evidence is not stopping drugs. It is a
structured review, and it has a literature of its own.

The process begins with a complete list — every prescription, every item
bought without one, and every supplement, since several over-the-counter sleep
aids and allergy medicines carry substantial anticholinergic activity and are
frequently omitted when patients list what they take.

Each item is then assessed for whether the original indication still applies,
whether the drug is achieving its purpose, whether a lower dose would do, and
whether an alternative with less anticholinergic activity exists. For several
of the classes involved, alternatives do exist and are actively preferred in
guidance for older adults.

Reduction is staged rather than simultaneous. Changing one drug at a time
makes it possible to attribute any change in symptoms, and reversing a change
that goes badly is straightforward.

And the outcome is monitored. Trials of deprescribing interventions have shown
reductions in burden scores; evidence that reducing burden improves cognition
is thinner, which is a limitation worth knowing in advance rather than
discovering afterwards.

That thinness is worth dwelling on for a moment, because it is where hope and
evidence diverge. Demonstrating that reducing exposure improves outcomes
requires a trial that randomizes patients to a reduction and follows them for
years, and the few such trials are small and short. It remains entirely
possible that the association reflects something other than a mechanism that
can be reversed by stopping. A review is still worth doing — the acute effects,
the fall risk and the simple question of whether every drug is still needed
justify it on their own.


The Five Questions for a Medication Review

Five questions make a medication review productive and none requires any
technical knowledge.

What is the total anticholinergic burden of this list. Most electronic systems
can compute it, and asking prompts the calculation.

Which of these still has a current indication. Drugs started for a temporary
reason have a documented tendency to continue indefinitely, and reviewing the
original purpose finds them.

Is there a lower-burden alternative for any of them, particularly for bladder
symptoms and for sleep, where alternatives are the most established.

What would be monitored if something changed, and over what period. A change
without a stated review point is difficult to evaluate later.

And what should not be touched. Some of these drugs are doing something
important, and knowing which ones are load-bearing is as useful as knowing
which are candidates for removal.


The bill, not the debate

The evidence here is real, dose-dependent, replicated — and its own authors
could not exclude that the drugs were prescribed for symptoms the disease had
already started causing. That is an argument for a medication review, which is
free and available on request, and not for stopping anything at home. Does
anyone currently see your whole list in one place?Connor Hill reads every reply.


Sources checked: Coupland et al. — Anticholinergic Drug Exposure and the Risk
of Dementia: A Nested Case-Control Study, JAMA Internal Medicine
<[link removed]> ·
Gray et al. —Cumulative Use of Strong Anticholinergics and Incident Dementia,
JAMA Internal Medicine
<[link removed]> ·
American Geriatrics Society — Beers Criteria for potentially inappropriate
medication use in older adults
<[link removed]> · National
Institute on Aging — safe use of medicines for older adults
<[link removed]>
·U.S. Food and Drug Administration — drug interactions and what to ask a
prescriber
<[link removed]>
·National Institute on Aging — delirium and sudden confusion in older adults
<[link removed]>


Connor Hill · InsightfulWord





You’re receiving this email from Insightful Word (IW), a brand of TerraTrance
Technologies, LLC.

Our mailing address: 200 Broadway Blvd NEAlbuquerque, NM 87102



Have a question or need assistance? Reply directly to this email or contact us
[email protected] <mailto:[email protected]>



The content of this email may not be copied, reproduced, forwarded, shared, or
distributed without the prior written consent of TerraTrance Technologies, LLC.

Privacy Policy <[link removed]>
Terms & Conditions <[link removed]>
Unsubscribe
<[link removed]>



© 2026 Insightful Word (IW). All Rights Reserved.